Esperanza Elías-Cabot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esperanza Elías-Cabot has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A.-K. Brehl
ScreenPoint Medical BV, Nijmegen, The Netherlands
1 shared publication- Alejandro Rodríguez-Ruiz
ScreenPoint Medical BV, Nijmegen, The Netherlands
1 shared publication José Luis Raya-Povedano
Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
1 shared publication- José Luis Raya-Povedano
Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
1 shared publication Marina Álvarez-Benito
Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
1 shared publication- Marina Álvarez-Benito
Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 19 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (4) , 1296-1305
AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial
Artificial intelligence (AI) systems have been demonstrated to improve the accuracy of screening mammograms. Here this prospective, paired, noninferiority clinical trial evaluated whether AI could safely reduce workload by excluding low-risk exams from radiologist reading. Between March 2022 and January 2024, 31,301 women were included in the trial and underwent routine mammograms. Two reading strategies were applied in parallel: standard double-blind reading and partially autonomous AI-supported screening, where cases classified by AI as low risk were assessed as normal and the rest were double read with AI support. The primary outcomes were radiologist workload, cancer detection rate and recall rate. In the AI strategy, radiologist workload was 63.6% lower; the cancer detection rate was 15.2% higher (95% confidence interval 6.6%, 24.4%), increasing from 6.3 of 1,000 to 7.3 of 1,000, P < 0.001; and the recall rate was not noninferior and was 14.8% higher (95% confidence interval 9.0%, 20.6%). Subanalyses by modality highlighted a similar workload reduction in digital mammography (−62.1%) and digital breast tomosynthesis (−65.5%). However, in digital mammography, the cancer detection rate increased by 1.6 of 1,000 and the recall rate by 1.3%, while both remained stable in digital breast tomosynthesis. These results demonstrate the feasibility of a partially automated AI workflow in breast cancer screening, avoiding human reading of studies classified as low risk. ClinicalTrials.gov: NCT04849776.
- 19 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (4) , 1296-1305
Top Cited PapersOpen AccessAI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial
Artificial intelligence (AI) systems have been demonstrated to improve the accuracy of screening mammograms. Here this prospective, paired, noninferiority clinical trial evaluated whether AI could safely reduce workload by excluding low-risk exams from radiologist reading. Between March 2022 and January 2024, 31,301 women were included in the trial and underwent routine mammograms. Two reading strategies were applied in parallel: standard double-blind reading and partially autonomous AI-supported screening, where cases classified by AI as low risk were assessed as normal and the rest were double read with AI support. The primary outcomes were radiologist workload, cancer detection rate and recall rate. In the AI strategy, radiologist workload was 63.6% lower; the cancer detection rate was 15.2% higher (95% confidence interval 6.6%, 24.4%), increasing from 6.3 of 1,000 to 7.3 of 1,000, P < 0.001; and the recall rate was not noninferior and was 14.8% higher (95% confidence interval 9.0%, 20.6%). Subanalyses by modality highlighted a similar workload reduction in digital mammography (−62.1%) and digital breast tomosynthesis (−65.5%). However, in digital mammography, the cancer detection rate increased by 1.6 of 1,000 and the recall rate by 1.3%, while both remained stable in digital breast tomosynthesis. These results demonstrate the feasibility of a partially automated AI workflow in breast cancer screening, avoiding human reading of studies classified as low risk. ClinicalTrials.gov: NCT04849776.
- Open Access
- 17 November 2023
- Published by Springer Nature in European Radiology
- Vol. 34 (6) , 3958-3966
Impact of real-life use of artificial intelligence as support for human reading in a population-based breast cancer screening program with mammography and tomosynthesis
Objectives: To evaluate the impact of using an artificial intelligence (AI) system as support for human double reading in a real-life scenario of a breast cancer screening program with digital mammography (DM) or digital breast tomosynthesis (DBT). Material and methods: We analyzed the performance of double reading screening with mammography and tomosynthesis after implementarion of AI as decision support. The study group consisted of a consecutive cohort of 1 year screening between March 2021 and March 2022 where double reading was performed with concurrent AI support that automatically detects and highlights lesions suspicious of breast cancer in mammography and tomosynthesis. Screening performance was measured as cancer detection rate (CDR), recall rate (RR), and positive predictive value (PPV) of recalls. Performance in the study group was compared using a McNemar test to a control group that included a screening cohort of the same size, recorded just prior to the implementation of AI. Results: A total of 11,998 women (mean age 57.59 years ± 5.8 [sd]) were included in the study group (5049 DM and 6949 DBT). Comparing global results (including DM and DBT) of double reading with vs. without AI support, we observed an increase in CDR, PPV, and RR by 3.2/‰ (5.8 vs. 9; p < 0.001), 4% (10.6 vs. 14.6; p < 0.001), and 0.7% (5.4 vs. 6.1; p < 0.001) respectively. Conclusion: AI used as support for human double reading in a real-life breast cancer screening program with DM and DBT increases CDR and PPV of the recalled women. Clinical relevance statement: Artificial intelligence as support for human double reading improves accuracy in a real-life breast cancer screening program both in digital mammography and digital breast tomosynthesis. Key Points: • AI systems based on deep learning technology offer potential for improving breast cancer screening programs. • Using artificial intelligence as support for reading improves radiologists’ performance in breast cancer screening programs with mammography or tomosynthesis. • Artificial intelligence used concurrently with human reading in clinical screening practice increases breast cancer detection rate and positive predictive value of the recalled women.
- 17 November 2023
- Published by Springer Nature in European Radiology
- Vol. 34 (6) , 3958-3966
Open AccessImpact of real-life use of artificial intelligence as support for human reading in a population-based breast cancer screening program with mammography and tomosynthesis
Objectives: To evaluate the impact of using an artificial intelligence (AI) system as support for human double reading in a real-life scenario of a breast cancer screening program with digital mammography (DM) or digital breast tomosynthesis (DBT). Material and methods: We analyzed the performance of double reading screening with mammography and tomosynthesis after implementarion of AI as decision support. The study group consisted of a consecutive cohort of 1 year screening between March 2021 and March 2022 where double reading was performed with concurrent AI support that automatically detects and highlights lesions suspicious of breast cancer in mammography and tomosynthesis. Screening performance was measured as cancer detection rate (CDR), recall rate (RR), and positive predictive value (PPV) of recalls. Performance in the study group was compared using a McNemar test to a control group that included a screening cohort of the same size, recorded just prior to the implementation of AI. Results: A total of 11,998 women (mean age 57.59 years ± 5.8 [sd]) were included in the study group (5049 DM and 6949 DBT). Comparing global results (including DM and DBT) of double reading with vs. without AI support, we observed an increase in CDR, PPV, and RR by 3.2/‰ (5.8 vs. 9; p < 0.001), 4% (10.6 vs. 14.6; p < 0.001), and 0.7% (5.4 vs. 6.1; p < 0.001) respectively. Conclusion: AI used as support for human double reading in a real-life breast cancer screening program with DM and DBT increases CDR and PPV of the recalled women. Clinical relevance statement: Artificial intelligence as support for human double reading improves accuracy in a real-life breast cancer screening program both in digital mammography and digital breast tomosynthesis. Key Points: • AI systems based on deep learning technology offer potential for improving breast cancer screening programs. • Using artificial intelligence as support for reading improves radiologists’ performance in breast cancer screening programs with mammography or tomosynthesis. • Artificial intelligence used concurrently with human reading in clinical screening practice increases breast cancer detection rate and positive predictive value of the recalled women.